FWBI
First Wave BioPharma, Inc. [FWBI] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
FWBI Stock Summary
Top 10 Correlated Stocks
FWBI
In the News
First Wave BioPharma To Present at the BIO Investor Forum
BOCA RATON, Fla., Sept. 15, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, President and CEO, will make a company presentation at the BIO Investor Forum being held October 17-18, 2023, at the Hilton San Francisco Union Square in San Francisco.
First Wave BioPharma stock soars in active trading after Sanofi license deal
Shares of First Wave BioPharma Inc. FWBI, +8.61% soared 71.7% in active premarket trading Thursday, after the biopharmaceutical company announced an agreement to license Capeserod to Sanofi SNY, -0.73%, which First Wave will repurpose and develop for gastrointestinal indications. Trading volume swelled to 6.5 million shares, already more than double the full-day average of about 2.6 million shares, and enough to make the stock the third-most actively traded in Thursday's premarket.
First Wave (FWBI) Down 32% on Cystic Fibrosis Study Setback
Initial data from First Wave's (FWBI) mid-stage study evaluating its investigational oral capsule in cystic fibrosis patients did not likely meet its primary endpoint.
First Wave (FWBI) Surges 33% on Finishing Enrolment in CF Study
First Wave (FWBI) completes enrolment in a mid-stage study evaluating its investigational oral capsule in patients with cystic fibrosis. Topline data from the study is expected next month.
First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference
BOCA RATON, Fla., May 15, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that James Sapirstein, Chief Executive Officer of First Wave BioPharma, will present at the 2023 BIO International Conference on Tuesday, June 6 11:45 AM in Room 104A. The conference is taking place June 5-8 in the Boston Convention & Exhibition Center in Boston, Massachusetts.
First Wave BioPharma to Present at the BIO CEO & Investor Conference
BOCA RATON, Fla., Jan. 30, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced James Sapirstein, Chairman, President and CEO, will present at the BIO CEO & Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City.
Why Is First Wave BioPharma (FWBI) Stock Up 30% Today?
Many Nasdaq stocks were in the red this morning, but not First Wave BioPharma (NASDAQ: FWBI ) stock. Indeed, First Wave shares were up substantially after the company announced an addition to its intellectual property (IP) portfolio governing a proprietary drug called adrulipase.
First Wave BioPharma to Present at Sequire Biotechnology Conference
BOCA RATON, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced James Sapirstein, Chairman, President and CEO, will present at the Sequire Biotechnology Conference being held virtually on February 2, 2023.
First Wave (FWBI) IND Filing Under FDA's Review, Stock Up
First Wave's (FWBI) stock gains as FDA reviews its IND amendment for the planned phase II study of an enhanced enteric microgranule delivery formulation of adrulipase.
First Wave BioPharma's CEO James Sapirstein to Present at Inaugural Roth Healthcare Opportunities Conference
BOCA RATON, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President, and CEO of First Wave BioPharma, will give a presentation and take investor meetings at the Inaugural Roth Healthcare Opportunities Conference taking place October 6, 2022, in New York City.
FWBI Financial details
FWBI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -1.84K | -1.46K | -2.86K | -1.39K | -23.09 | |
| Operating cash flow per share | -1.48K | -1.31K | -828.71 | -759.67 | -31.11 | |
| Free cash flow per share | -1.49K | -1.32K | -829.02 | -1K | -31.11 | |
| Cash per share | 151.57 | 16.46 | 447.69 | 194.07 | 1.9 | |
| Book value per share | 608.52 | 432.41 | -195.01 | -184.02 | 3.82 | |
| Tangible book value per share | 269.12 | -63.36 | -559.36 | -229 | 1.47 | |
| Share holders equity per share | 608.52 | 432.41 | -195.01 | -184.02 | 3.82 | |
| Interest debt per share | 48.54 | 190.9 | 477.78 | 24.51 | 1.25 | |
| Market cap | 18.68M | 23.32M | 27.58M | 12.9M | 4.4M | |
| Enterprise value | 17.82M | 24.75M | 22.15M | 5.68M | 3.92M | |
| P/E ratio | -1.38 | -1.49 | -0.71 | -0.22 | -0.27 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -1.72 | -1.66 | -2.46 | -0.4 | -0.2 | |
| PFCF ratio | -1.71 | -1.66 | -2.46 | -0.3 | -0.2 | |
| P/B Ratio | 4.18 | 5.05 | -10.45 | -1.65 | 1.61 | |
| PTB ratio | 4.18 | 5.05 | -10.45 | -1.65 | 1.61 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -1.41 | -1.8 | -0.86 | -0.1 | -0.3 | |
| EV to operating cash flow | -1.64 | -1.76 | -1.97 | -0.18 | -0.18 | |
| EV to free cash flow | -1.63 | -1.76 | -1.97 | -0.13 | -0.18 | |
| Earnings yield | -0.72 | -0.67 | -1.4 | -4.58 | -3.77 | |
| Free cash flow yield | -0.58 | -0.6 | -0.41 | -3.3 | -5.07 | |
| Debt to equity | 0.06 | 0.35 | -0.24 | -0.13 | 0.32 | |
| Debt to assets | 0.03 | 0.18 | 0.05 | 0.09 | 0.16 | |
| Net debt to EBITDA | 0.07 | -0.1 | 0.21 | 0.13 | 0.04 | |
| Current ratio | 1.6 | 0.8 | 0.51 | 0.77 | 1.37 | |
| Interest coverage | -131.88 | -33.98 | -4.53 | -5.26K | -798.42 | |
| Income quality | 0.8 | 0.92 | 0.34 | 0.55 | 1.53 | |
| Dividend Yield | 0 | 0.07 | 0.3 | 349.46K | 0.01 | |
| Payout ratio | 0 | -0.11 | -0.21 | -76.29K | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.33 | 0.59 | 0.38 | 0.16 | 0.31 | |
| Capex to operating cash flow | 0.01 | 0 | 0 | 0.32 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.07 | -0.02 | -0.01 | -19.03 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 5.02K | 3.77K | 3.54K | 2.4K | 44.53 | |
| ROIC | -2.82 | -2.41 | 16.19 | 9.31 | -3.68 | |
| Return on tangible assets | -2.72 | -4.33 | -4.85 | -5.98 | -4.42 | |
| Graham Net | 67.78 | -199.65 | -671.21 | -267.34 | -1.76 | |
| Working capital | 1.8M | -877.35K | -7.68M | -2.88M | 929.27K | |
| Tangible asset value | 1.98M | -676.53K | -7.57M | -9.73M | 1.06M | |
| Net current asset value | 1.8M | -877.35K | -7.69M | -10.19M | 715.21K | |
| Invested capital | 0.06 | 0.35 | -0.24 | -0.13 | 0.32 | |
| Average receivables | 2.14M | 2.9M | 1.59M | 275.74K | 46.51K | |
| Average payables | 1.45M | 2.21M | 1.89M | 2.12M | 1.7M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -3.03 | -3.38 | 14.66 | 7.55 | -6.05 | |
| Capex per share | -7.55 | -2.26 | -0.31 | -242.79 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -52.1 | 19.2 | -7.93 | -12.55 | -1.84 | |
| Operating cash flow per share | -44.16 | -18.6 | -7.79 | -8.73 | -1.22 | |
| Free cash flow per share | -44.16 | -18.6 | -7.79 | -8.73 | -1.22 | |
| Cash per share | 11.12 | 7.24 | 1.9 | 6.34 | 0.54 | |
| Book value per share | -136.65 | -9.97 | 3.82 | 8.33 | 0.39 | |
| Tangible book value per share | -153.55 | -17.46 | 1.47 | 3.16 | -0.35 | |
| Share holders equity per share | -136.65 | -9.97 | 3.82 | 8.33 | 0.39 | |
| Interest debt per share | 4.58 | 1.3 | 1.24 | 2.01 | 0.18 | |
| Market cap | 4.36M | 2.37M | 4.4M | 873.17K | 3.63M | |
| Enterprise value | 3.68M | 1.01M | 3.92M | -546.41K | 2.8M | |
| P/E ratio | -0.2 | 0.13 | -0.19 | -0.05 | -0.22 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -0.95 | -0.56 | -0.79 | -0.31 | -1.32 | |
| PFCF ratio | -0.95 | -0.56 | -0.79 | -0.31 | -1.32 | |
| P/B Ratio | -0.31 | -1.04 | 1.61 | 0.32 | 4.12 | |
| PTB ratio | -0.31 | -1.04 | 1.61 | 0.32 | 4.12 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -0.68 | 0.23 | -0.99 | 0.13 | -0.67 | |
| EV to operating cash flow | -0.8 | -0.24 | -0.7 | 0.19 | -1.01 | |
| EV to free cash flow | -0.8 | -0.24 | -0.7 | 0.19 | -1.01 | |
| Earnings yield | -1.24 | 1.85 | -1.29 | -4.68 | -1.15 | |
| Free cash flow yield | -1.05 | -1.79 | -1.27 | -3.26 | -0.76 | |
| Debt to equity | -0.03 | -0.13 | 0.32 | 0.24 | 0.46 | |
| Debt to assets | 0.12 | 0.06 | 0.16 | 0.12 | 0.09 | |
| Net debt to EBITDA | 0.13 | -0.31 | 0.12 | 0.35 | 0.2 | |
| Current ratio | 0.1 | 0.38 | 1.37 | 1.34 | 0.72 | |
| Interest coverage | -1.68K | 5.09K | -368.1 | -452.03 | -807.58 | |
| Income quality | 0.85 | -0.97 | 1.4 | 0.7 | 0.66 | |
| Dividend Yield | 0 | 0 | 0.01 | 0.1 | 0 | |
| Payout ratio | 0 | 0 | -0.01 | -0.02 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.45 | 0.37 | 0.31 | 0.3 | 0.39 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 400.24 | 65.61 | 26.09 | 48.48 | 4.01 | |
| ROIC | 0.4 | -2.6 | -0.83 | -1.13 | -2.73 | |
| Return on tangible assets | -2.49 | 1.5 | -1.52 | -1.06 | -1.58 | |
| Graham Net | -162.83 | -22.4 | -1.76 | -2.28 | -0.97 | |
| Working capital | -15.49M | -4.15M | 929.27K | 905.02K | -907.46K | |
| Tangible asset value | -15.95M | -3.99M | 1.06M | 1.03M | -802.22K | |
| Net current asset value | -16.33M | -4.38M | 715.21K | 708.49K | -1.09M | |
| Invested capital | -0.03 | -0.13 | 0.32 | 0.24 | 0.46 | |
| Average receivables | 49.24K | 131.21K | 142.5K | 56.51K | 10K | |
| Average payables | 3.71M | 3.77M | 2.15M | 594.9K | 1.03M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.38 | -1.93 | -2.08 | -1.51 | -4.75 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
FWBI Frequently Asked Questions
What is First Wave BioPharma, Inc. stock symbol ?
First Wave BioPharma, Inc. is a US stock , located in Boca raton of Fl and trading under the symbol FWBI
What is First Wave BioPharma, Inc. stock quote today ?
First Wave BioPharma, Inc. stock price is $0.325 today.
Is First Wave BioPharma, Inc. stock public?
Yes, First Wave BioPharma, Inc. is a publicly traded company.
Company Profile
- Volume Average 3.66M
- Market Capitalization 2.49M
- Employee 10
- CEO Mr. James R. Sapirstein M.B.A., R.Ph.
- Headquarters Boca Raton,FL,US
- IPO Date 2016-10-11
-
Website
https://www.firstwavebio.com 
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
